The company fully deploys the work in the second half of the year
Release time:
2020-08-17
Inventory of Work Gains and Losses in the First Half of the Year
Planning of Epidemic Enterprise Development Ideas
Company Fully Deploys Work in the Second Half of the Year
News 7# October 17 , 18 , Group Company 2020 First Half of the Year Work Analysis Meeting Held in Peak Building of Group Headquarters to Summarize and Review Work in the First Half of the First Half, make arrangements for the second half of the year. At the
meeting, various professional companies, directly affiliated enterprises and Shanghai North Carolina Company successively reported the work situation in the first half of the year, focused on analyzing the problems existing in the work, and put forward the work plan for the second half of the year. The heads of various functional departments of the group made a summary and analysis of the work in the first half of the year. Xiang Chongping, deputy general manager of the group company, Chen Tianci, chairman of the board of supervisors, and Lan Xiaolong, head of finance, respectively made a summary and analysis on human resources management, bidding management, and the company's financial situation in the first half of the year. Zhu Jianwei, secretary of the board of directors, expounded some problems that should be paid attention to in the future work from the perspective of the management and development of listed companies.
Group General Manager Yu Jianhong made a detailed analysis of the composition of the first half of the year and the reasons for the changes in economic indicators, taking into account the situation of the same period last year; he pointed out the highlights of the work, such as the effective prevention and control of the new crown epidemic, the progress of different degrees of production and technical indicators, and the improvement of enterprise management; in particular, Guizhou peak overtime to grasp the project construction, Daye peak epidemic during the organization of production and equipment maintenance, Jinhua pharmaceutical companies and large pharmacies to give up the holiday overtime to organize anti-epidemic materials and other praise.
According to the current actual situation of the company, Yu Jianhong deployed the key work in the second half of the year. The main contents include: the group company should continue to focus on new strategic development projects, further promote various management upgrades, and improve the functional responsibilities and evaluation system of the group's functional departments and offices with platform enabling thinking; The cement sector should pay attention to the production, production and marketing of Guizhou peak, the mine renovation work of Daye peak and Yunnan peak, and the further integration of the cement industry; the pharmaceutical sector should pay close attention to promoting the product introduction and follow-up operation mode research of international projects, do a good job in market expansion and bidding for the third national centralized purchase, further strengthen the construction of research and development system, do a good job in the future operation and development direction and development mode analysis and research of pharmaceutical commercial business, and do a good job in the technical transformation of API workshop. Shanghai North Carolina should further straighten out the management organization structure and speed up the construction progress of the technical transformation project, do a good job in the connection of external entrusted processing, internal production organization and sales; Jianfeng International Trade Company should focus on the construction of the third phase of warehousing and logistics, and speed up the construction, optimization, operation and investment promotion of the network freight platform; cable companies should make further efforts to do a good job in cost control and product quality improvement, give full play to the advantages of cost, quality and flexible operation, expand new customers, consolidate old customers, and improve viability; peak health to focus on good management norms, continue to optimize the business structure, product structure, management structure, reverse the business situation.
In order to enable managers at all levels to have a deeper understanding of the work arrangement in the second half of the year, Yu Jianhong also analyzed the current macroeconomic environment and the industry situation of the company's two main businesses, and proposed to cultivate the advantages of value concept. Give full play to the functional advantages of the group platform and enhance the group's empowerment; Cultivate the advantages of value chain and business operation mode of each business sector; Cultivate the advantages of operation and management; Strengthen technological innovation and enhance technological advantages; cultivate the advantages of the workforce, enhance the ability of enterprises to resist risks through continuous innovation and change, and promote better high-quality development of spikes. Jiang Xiaomeng, chairman of
Group Company, made a concluding speech at the meeting and put forward requirements for the key work in the second half of the year (details are published separately in this edition). (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page